Second quarter (April-
· Other operating income amounted to KSEK 2,782 (1,141)
· Operating loss was KSEK -7,292 (-11,307 of which impairment loss on patents amounted to KSEK -4,573) KSEK
· Loss for the period totalled -7,976 (-11,213) KSEK
· Cash flow from operating activities was KSEK -9,003 (-6,531)
· Loss per share was
Period (January-
· Other operating income amounted to KSEK 4,195 (1,994)
· Operating loss was KSEK -13,952 (-18,069)
· Loss for the period totalled KSEK -14,197 (-17,856)
· Cash flow from operating activities was KSEK -10,788 (-18,562)
· Loss per share was
Significant events in the second quarter
· In June,
· From
·
· The ongoing Corona pandemic has so far had some impact on the company's operations. During the pandemic, Radboud University Medical Center has worked at reduced capacity. In collaboration with Radboud,
Significant events in the second quarter
· At the end of January, Crown
· A rights issue underwritten to 88% was completed in March, and generated net proceeds of MSEK 20.6 for
· In March, disbursements from the EU's Horizon 2020 programme resumed and KEUR 550 was paid out.
Significant events after the end of the period
· In july, Åsa Schiött was appointed new Chief Scientific Officer (CSO) and Vicky Venizelos Chief Regulatory Officer (CRO).
· No other significant events occurred after the end of the period that affected the results or financial position.
If you have any questions, please contact:
Phone: +46 (0) 709 18 00 10
E-mail: anders.karlsson@idogen.com
Certified Adviser
Phone: +46 (0)8-463 80 00
E-mail: certifiedadviser@penser.se.
https://news.cision.com/idogen/r/idogen-ab-interim-report,c3180495
https://mb.cision.com/Main/12368/3180495/1296808.pdf
(c) 2020 Cision. All rights reserved., source